Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 38-43

  Puolakka, K ^a   Blafield H ^b   Kauppi, M ^c   Luosujarvi R ^d   Peltomaa, R ^d   Leikola Pelho, T ^e   Sennfalt, K ^e   Beresniak, A ^f,g  

^a Lappeenranta Central Hospital   (Finland)

^b SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^c RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e BRISTOL MYERS SQUIBB   (United States)

^f DATA MINING INTERNATIONAL   (Switzerland)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Biologics; Cost effectiveness; Modeling; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FINLAND; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 84860681286     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010038     Document Type: Article

References (28)

1. Puolakka K, Kautiainen H, Pohjolainen T, Virta L. Rheumatoid arthritis remains a threat to work productivity: a nationwide registerbased uncidence study from finland. Scand J Rheumatol 2010; 39: 436-438.
2. Hyrich K, Lunt M, Watson K, Symmons D, Silman A. Register BSfRB. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
3. Gabriel S, Drummond M, Maetzel A, et al. Omeract 6 economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003; 30: 887-890.
4. Russell A, Beresniak A, Bessette L, et al. Cost effectiveness modeling of abatacept versus other biologic agents in dmards and anti-tnf inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2008; 28(4): 403-412.
5. Genovese M, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 547-554.
6. Genovese M, Becker J, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-1123.
7. Bombardieri S, Ruiz A, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of tnf-antagonist therapy in clinical practice. Rheumatology 2007; 46: 1191-1199.
8. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase iii trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-2806.
9. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum 2007; 56: 3896-3908.
10. Karlson J, Kristensen L, Kapetanovic M, Gulfe A, Saxne T, Geborck P. Treatment response to a second or third tnf-inhibitor in ra: Results from the south swedish arthritis treatment group register. Rheumatology 2008; 47: 507-513.
11. Beresniak A, Gossec L, Goupille P, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol 2011; 38(3): 439-445.
12. Saraux A, Gossec L, Goupille P, et al. Cost-effectiveness modeling of biological treatment sequences in moderate to severe rheumatoid arthritis in france. Rheumatology (Oxford) 2010; 49: 733-740.
13. Cimmino M, Leardini G, Salaffi F, et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-tnf inadequate responders in italy: A modelling approach. Clin Exp Rheumatol 2011; 29(4): 633-641.
14. Beresniak A, Ariza-Ariza R, Garcia-Llorente J, Ramirez-Arellano A, Dupont D. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam 2011; 2011; 727634.
15. Beresniak A, Russell A, Haraoui B, Bessette L, Bombardier C, Duru G. Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007; 34: 2193-2200.
16. Osiri M, Kamolratanakul P, Maetzel A, Tugwell P. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis. Rheumatol Int 2007; 27: 1063-1069.
17. Davies A, Cifaldi M, Segurado O, Weisman M. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009; 36: 16-26.
18. Kielhorn A, Porter D, Diamantopoulos A, Lewis G. Uk cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin 2008; 24: 2639-2650.
19. Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol 2008; 35: 1745-1753.
20. Wailoo A, Bansback N, Brennan A, Michaud K, Nixon R, Wolfe F. Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis. Arthritis Rheum 2008; 58: 939-946.
21. Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyannis N. Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics 2002; 20: 463-473.
22. McGregor M, Caro J. Qalys: are they helpful to decision makers? Pharmacoeconomics 2006; 24: 947-952.
23. Marra C, Woolcott J, Kopec J, et al. A comparison of generic, indirect utility measures (the hui2, hui3, sf-6d and the eq-5d) and disease-specific instruments (the raqol and the haq) in rheumatoid arthritis. Soc Sci Med 2005; 60: 1571-1582.
24. Conner-Spady B, Suarez-Almazor M. Variation in the estimation of quality adjusted life-years by different preference-based instruments. Med Care 2003; 41: 791-801.
25. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med 2010; 363: 1495-1497.
26. Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health states. Pharmacoeconomics 2008; 26: 395-408.
27. Maetzel A, Tugwell P, Boers M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a reference case. J Rheumatol 2003; 30: 891-896.
28. Emery P. Review of health economics modeling in rheumatoid arthritis. Pharmacoeconomics 2004; 22: 55-69.